
Microscopy image of mouse neurons.
Image Credit: Christophe Leterrier, NeuroCyto Lab, INP, Marseille, France, via NIH BRAIN Initiative
Scientific Frontline: Extended "At a Glance" Summary: Precision DNA Editing for Dravet Syndrome
The Core Concept: Adenine base editing, a highly targeted form of genetic medicine, has been successfully deployed in a preclinical mouse model to correct the specific DNA mutation (SCN1A) responsible for Dravet syndrome, a severe and often fatal form of childhood epilepsy.
Key Distinction/Mechanism: Unlike conventional treatments that require ongoing medication to manage neurological symptoms, this method offers a potential one-time genetic correction. It utilizes an adenine base editor to rewrite a single DNA letter within the brain without cutting both DNA strands. This preserves genomic integrity, reduces off-target effects, and successfully restores the cell's natural ability to produce functional Nav1.1 channels.
Origin/History: The breakthrough builds on a collaboration between The Jackson Laboratory (JAX), the Broad Institute (incorporating the work of gene-editing pioneer David Liu), and the Children’s Hospital of Philadelphia.





.jpg)

.jpg)
.png)




.jpg)